238 related articles for article (PubMed ID: 24560023)
1. Introduction and commentary: paving the way for biosimilars in oncology, part 2: focus on safety and clinical trial considerations.
Abraham J
Semin Oncol; 2014 Feb; 41 Suppl 1():S1-2. PubMed ID: 24560023
[No Abstract] [Full Text] [Related]
2. Introduction and commentary: Paving the way for biosimilars in oncology.
Abraham J
Semin Oncol; 2013 Dec; 40 Suppl 1():S1-4. PubMed ID: 24267943
[No Abstract] [Full Text] [Related]
3. Developing clinical trials for biosimilars.
Bui LA; Taylor C
Semin Oncol; 2014 Feb; 41 Suppl 1():S15-25. PubMed ID: 24560024
[TBL] [Abstract][Full Text] [Related]
4. Biosimilars in oncology: from development to clinical practice.
Rak Tkaczuk KH; Jacobs IA
Semin Oncol; 2014 Apr; 41 Suppl 3():S3-S12. PubMed ID: 24767633
[TBL] [Abstract][Full Text] [Related]
5. Biosimilar safety considerations in clinical practice.
Choy E; Jacobs IA
Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025
[TBL] [Abstract][Full Text] [Related]
6. Introduction and commentary: Paving the way for biosimilars in oncology, part 3: Clinical and economic impact of oncology biosimilars.
Abraham J
Semin Oncol; 2014 Apr; 41 Suppl 3():S1-2. PubMed ID: 24767631
[No Abstract] [Full Text] [Related]
7. [The development of biosimilars in oncology].
Jiang SY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2017 Oct; 39(10):721-725. PubMed ID: 29061013
[TBL] [Abstract][Full Text] [Related]
8. Introduction and commentary: Biosimilars-clinical trial and safety considerations.
Reinisch W
Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S1. PubMed ID: 26058548
[No Abstract] [Full Text] [Related]
9. Developing oncology biosimilars: an essential approach for the future.
Abraham J
Semin Oncol; 2013 Dec; 40 Suppl 1():S5-24. PubMed ID: 24267944
[TBL] [Abstract][Full Text] [Related]
10. Education strategy for the implementation of oncology biosimilars essential for operational and patient safety in Alberta, Canada.
Garg M; Chatterjee A; Chambers CR
J Oncol Pharm Pract; 2021 Jul; 27(5):1189-1194. PubMed ID: 33896268
[TBL] [Abstract][Full Text] [Related]
11. Regulatory and clinical considerations for biosimilar oncology drugs.
Bennett CL; Chen B; Hermanson T; Wyatt MD; Schulz RM; Georgantopoulos P; Kessler S; Raisch DW; Qureshi ZP; Lu ZK; Love BL; Noxon V; Bobolts L; Armitage M; Bian J; Ray P; Ablin RJ; Hrushesky WJ; Macdougall IC; Sartor O; Armitage JO
Lancet Oncol; 2014 Dec; 15(13):e594-e605. PubMed ID: 25456378
[TBL] [Abstract][Full Text] [Related]
12. Emerging Opportunities and Challenges of Biosimilars in Oncology Practice.
Lyman GH
J Oncol Pract; 2017 Sep; 13(9_suppl):7s-9s. PubMed ID: 28898591
[No Abstract] [Full Text] [Related]
13. Nursing Roles: Clinical Implications Regarding Trends, Administration, and Education for Biosimilars in Oncology Practice.
Zack E
Clin J Oncol Nurs; 2018 Oct; 22(5):21-26. PubMed ID: 30239530
[TBL] [Abstract][Full Text] [Related]
14. Biosimilars: Considerations for Oncology Nurses
.
Vizgirda V; Jacobs I
Clin J Oncol Nurs; 2017 Apr; 21(2):E54-E60. PubMed ID: 28315542
[TBL] [Abstract][Full Text] [Related]
15. Clinical development of CT-P10 and other biosimilar cancer therapeutics.
Kim WS; Coiffier B; Kwon HC; Kim S
Future Oncol; 2017 May; 13(15s):31-44. PubMed ID: 28482700
[TBL] [Abstract][Full Text] [Related]
16. The evolution of biosimilars in oncology, with a focus on trastuzumab.
Nixon NA; Hannouf MB; Verma S
Curr Oncol; 2018 Jun; 25(Suppl 1):S171-S179. PubMed ID: 29910660
[TBL] [Abstract][Full Text] [Related]
17. Are Biosimilars the Future of Oncology and Haematology?
Zinzani PL; Dreyling M; Gradishar W; Andre M; Esteva FJ; Boulos S; González Barca E; Curigliano G
Drugs; 2019 Oct; 79(15):1609-1624. PubMed ID: 31541401
[TBL] [Abstract][Full Text] [Related]
18. Clinical Trials: Nursing Roles During the Approval Process and Pharmacovigilance of Biosimilars.
Sugay J
Clin J Oncol Nurs; 2018 Oct; 22(5):27-32. PubMed ID: 30239528
[TBL] [Abstract][Full Text] [Related]
19. [Consensus document on the use of granulocyte colony stimulating factor biosimilars for correction of neutropenia in cancer patients].
Aranda Aguilar E; Camps Herrero C; Carrato Mena A; Clopés Estela A; Cruz Hernández JJ; Delgado Sánchez O; Díaz-Rubio García E; Domínguez-Gil Hurlé A; Dorantes Calderón B; García Alfonso P; Herrero Ambrosio A
Farm Hosp; 2010 Mar; 34 Suppl 1():45-50. PubMed ID: 20920857
[No Abstract] [Full Text] [Related]
20. Knowledge and awareness of biosimilars among oncology patients in Colorado, USA.
Ismailov RM; Khasanova ZD; Gascon P
Future Oncol; 2019 Aug; 15(22):2577-2584. PubMed ID: 31339051
[No Abstract] [Full Text] [Related]
[Next] [New Search]
